RANI

Rani Therapeutics Holdings, Inc. Class A Common Stock

0.56

USD

-0.01

-2.47%

Nov 10, 15:58 UTC -5

Closed

After-Market

0.55

-0.01

-1.45%

Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) Earnings

RANI Earnings Reports

Positive Surprise Ratio

RANI beat 18 of 22 last estimates.

82%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Rani Therapeutics Holdings, Inc. Class A Common Stock earnings per share and revenue

On Nov 09, 2026, RANI reported earnings of -0.04 USD per share (EPS) for Q3 26, beating the estimate of -0.04 USD, resulting in a 17.53% surprise. Revenue reached 1.71 million, compared to an expected 1.31 million, with a 31.03% difference.

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Rani Therapeutics Holdings, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Rani Therapeutics Holdings, Inc. Class A Common Stock reported EPS of -$0.04, beating estimates by 17.53%, and revenue of $1.71M, 31.03% above expectations.

How did the market react to Rani Therapeutics Holdings, Inc. Class A Common Stock's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Rani Therapeutics Holdings, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Rani Therapeutics Holdings, Inc. Class A Common Stock's next earnings report?

Based on -- analysts, Rani Therapeutics Holdings, Inc. Class A Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.